Injection Drug Users Not Accurately Reporting HIV Status

Study participants are not always open about their HIV status, or about whether or not they are taking antiretroviral therapy (ART), a new study finds.

A team of investigators from the United States, Ukraine, and Indonesia decided to check whether people who inject drugs (PWID) accurately self-reported HIV and antiretroviral drug status when entering an HIV prevention study.

The team examined samples collected upon enrollment from 482 HIV-positive patients. Each of the patients had separately been asked about HIV status and whether they had used antiretroviral (ARV) drugs. Of the 72 patients who tested positive for ARV drugs, 39 patients reported being on ART; the other 33 said they were not on ART.

When asked their HIV status, 213 patients said they did not know their status. Yet, 30 of those patients had ARV drugs in their systems at enrollment, and half of those had ARV detected during the screening visit.

“There are many reasons individuals may choose not to disclose their HIV status or HIV treatment,” corresponding author Susan H. Eshleman, MD, PhD, of the Johns Hopkins University School of Medicine told MD Magazine®“Some individuals may also not understand study questionnaires. There may also be errors in data collection in trials and other research settings.”

Eshleman said she and her colleagues were not surprised by the findings, since they match with similar findings from other cohorts. She also cautioned that these issues are nuanced and will vary from setting to setting and from cohort to cohort.

Eshleman said given that multi-drug ART is primarily used for HIV, “[s]omeone taking these medications for treatment would be aware of their HIV status.”

However, she said some patients might not want to disclose that they are on treatment because doing so would expose their HIV status. Successful ART can reduce the risk of HIV transmission, something that theoretically might make a person more willing to be upfront about his or her status. However, Eshleman noted that some patients may not be aware that treatment reduces their risk of transmitting the disease.

Eshleman said the question of ARV use is also complicated because the drugs are used differently in different countries and settings. For instance, country-specific guidelines set different regulations for the use of the drugs from one country to the next. The affordability and availability of the drugs also varies from place to place, as do local care practices.

“Stigma and other factors may impact whether an individual seeks care or uses ARV drugs for PrEP, PEP, treatment, or other reasons, and whether they chose to disclose HIV status or ARV drug use to research staff or others,” she added.

The authors concluded that given the likelihood of inaccuracies in self-reports of HIV or ARV status, people conducting research may need to use ARV drug testing in order to confirm HIV status or ARV use.

The study, “Use of Antiretroviral Drug Testing to Assess the Accuracy of Self-reported Data from HIV-Infected People Who Inject Drugs,” was published in AIDS and Behavior.
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Study explores the efficiency and accuracy of aspirin in colorectal cancer prevention.
Longitudinal study of direct-acting antivirals for hepatitis C virus infection finds that treatment provides clinical benefit beyond virologic response, reducing risk for both all-cause mortality and for liver cancer.
A novel method of inactivating hepatitis C virus in donor lungs could increase transplantations for patients with end stage lung disease.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$